Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

An Insight of Clinical Evidence of Ayurveda Interventions in the Management of COVID-19 Patients

Author(s): Naina Mohamed Pakkir Maideen*, Rajkapoor Balasubramanian, Gobinath Manavalan, Kumar Balasubramanian, Nivedhitha Subramanian, Thirumal Murugesan and Vasanth Kumar Solaimalai

Volume 22, Issue 6, 2022

Published on: 17 June, 2022

Article ID: e210322202491 Pages: 9

DOI: 10.2174/1871526522666220321152504

Price: $65

Abstract

Background: Coronavirus disease 2019 (COVID-19) was caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and patients with COVID-19 may be treated with traditional medicine like Ayurveda alone or in combination with standard allopathic treatment, as Ayurveda is one of the oldest traditional medicinal systems followed by millions around the world.

Methods: The literature was searched in databases such as LitCOVID, Google Scholar, Science Direct, EBSCO, Scopus, Web of Science, EMBASE, and reference lists to identify articles relevant to the use of Ayurvedic medicines in the management of COVID-19.

Results: Several clinical studies have determined the efficacy of Ayurvedic medicines and formulations in the management of patients with COVID-19.

Conclusion: The Ayurvedic medicines and formulations with antiviral, antioxidant, anti-inflammatory, and immunomodulatory properties could be used along with standard allopathic medicines to assist in the earlier detection of virus, speedy recovery of patients with COVID-19, faster discharge from hospitals, and the prevention of further deterioration.

Keywords: SARS CoV-2, COVID-19, ayurvedic medicines, shamshamani vati, chyawanprash, ashwagandha (Withania somnifera), guduchi (Tinospora cordifolia), pippali (Piper longum), anuthaila, agastya haritaki rasayana, Triphala churna, Rasayana churna.

Graphical Abstract

[1]
Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020; 5(4): 536-44.
[http://dx.doi.org/10.1038/s41564-020-0695-z] [PMID: 32123347]
[2]
WHO Coronavirus (COVID-19) Dashboard. Available at: https://covid19.who.int/ Accessed on August 26, 2021.
[3]
Greenhalgh T, Jimenez JL, Prather KA, Tufekci Z, Fisman D, Schooley R. Ten scientific reasons in support of airborne transmission of SARS-CoV-2. Lancet 2021; 397(10285): 1603-5.
[http://dx.doi.org/10.1016/S0140-6736(21)00869-2] [PMID: 33865497]
[4]
Bulfone TC, Malekinejad M, Rutherford GW, Razani N. Out-door transmission of SARS-CoV-2 and other respiratory virus-es: a systematic review. J Infect Dis 2021; 223(4): 550-61.
[http://dx.doi.org/10.1093/infdis/jiaa742] [PMID: 33249484]
[5]
Ni W, Yang X, Yang D, et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care 2020; 24(1): 422.
[http://dx.doi.org/10.1186/s13054-020-03120-0] [PMID: 32660650]
[6]
Li Y, Zhou W, Yang L, You R. Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor. Pharmacol Res 2020; 157: 104833.
[http://dx.doi.org/10.1016/j.phrs.2020.104833] [PMID: 32302706]
[7]
Huang Y, Yang C, Xu XF, Xu W, Liu SW. Structural and func-tional properties of SARS-CoV-2 spike protein: potential antivi-rus drug development for COVID-19. Acta Pharmacol Sin 2020; 41(9): 1141-9.
[http://dx.doi.org/10.1038/s41401-020-0485-4] [PMID: 32747721]
[8]
Rahman N, Basharat Z, Yousuf M, Castaldo G, Rastrelli L, Khan H. Virtual screening of natural products against Type II transmembrane serine protease (TMPRSS2), the priming agent of coronavirus 2 (SARS-CoV-2). Molecules 2020; 25(10): 2271.
[http://dx.doi.org/10.3390/molecules25102271] [PMID: 32408547]
[9]
Malik YA. Properties of coronavirus and SARS-CoV-2. Malays J Pathol 2020; 42(1): 3-11.
[PMID: 32342926]
[10]
Shamsi A, Mohammad T, Anwar S, et al. Potential drug targets of SARS-CoV-2: From genomics to therapeutics. Int J Biol Macromol 2021; 177: 1-9.
[http://dx.doi.org/10.1016/j.ijbiomac.2021.02.071] [PMID: 33577820]
[11]
Hirashima T, Arai T, Kitajima H, et al. Factors significantly associated with COVID-19 severity in symptomatic patients: A retrospective single-center study. J Infect Chemother 2021; 27(1): 76-82.
[http://dx.doi.org/10.1016/j.jiac.2020.09.022] [PMID: 33051144]
[12]
Boechat JL, Chora I, Morais A, Delgado L. The immune re-sponse to SARS-CoV-2 and COVID-19 immunopathology - Current perspectives. Pulmonology 2021; 27(5): 423-37.
[http://dx.doi.org/10.1016/j.pulmoe.2021.03.008] [PMID: 33867315]
[13]
Rabaan AA, Al-Ahmed SH, Muhammad J, et al. Role of in-flammatory cytokines in COVID-19 patients: A review on mo-lecular mechanisms, immune functions, immunopathology and immunomodulatory drugs to counter cytokine storm. Vaccines (Basel) 2021; 9(5): 436.
[http://dx.doi.org/10.3390/vaccines9050436] [PMID: 33946736]
[14]
Lowery SA, Sariol A, Perlman S. Innate immune and inflamma-tory responses to SARS-CoV-2: Implications for COVID-19. Cell Host Microbe 2021; 29(7): 1052-62.
[http://dx.doi.org/10.1016/j.chom.2021.05.004] [PMID: 34022154]
[15]
Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 2021; 184(4): 861-80.
[http://dx.doi.org/10.1016/j.cell.2021.01.007] [PMID: 33497610]
[16]
Nielsen SS, Vibholm LK, Monrad I, et al. SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severi-ty. EBioMedicine 2021; 68: 103410.
[http://dx.doi.org/10.1016/j.ebiom.2021.103410] [PMID: 34098342]
[17]
Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol 2020; 20(6): 355-62.
[http://dx.doi.org/10.1038/s41577-020-0331-4] [PMID: 32376901]
[18]
Reusch N, De Domenico E, Bonaguro L, et al. Neutrophils in COVID-19. Front Immunol 2021; 12: 652470.
[http://dx.doi.org/10.3389/fimmu.2021.652470] [PMID: 33841435]
[19]
Baqi HR, Farag HA, El Bilbeisi AH, Askandar RH, El Afifi AM. Oxidative stress and its association with COVID-19: A narrative review Kurdistan J Appl Res 2020; 97-105.
[http://dx.doi.org/10.24017/covid.11]
[20]
Kozlov EM, Ivanova E, Grechko AV, Wu WK, Starodubova AV, Orekhov AN. Involvement of oxidative stress and the in-nate immune system in SARS-CoV-2 infection. Diseases 2021; 9(1): 17.
[http://dx.doi.org/10.3390/diseases9010017] [PMID: 33668325]
[21]
Sindona C, Schepici G, Contestabile V, Bramanti P, Mazzon E. NOX2 activation in COVID-19: Possible implications for neu-rodegenerative diseases. Medicina (Kaunas) 2021; 57(6): 604.
[http://dx.doi.org/10.3390/medicina57060604] [PMID: 34208136]
[22]
Maideen NMP. Recent updates in the pharmacological manage-ment of COVID-19. Letters in Applied NanoBioScience 2021; 1: 1969-80.
[http://dx.doi.org/10.33263/LIANBS101.19691980]
[23]
Colafrancesco S, Scrivo R, Barbati C, Conti F, Priori R. Target-ing the immune system for pulmonary inflammation and cardi-ovascular complications in COVID-19 patients. Front Immunol 2020; 11: 1439.
[http://dx.doi.org/10.3389/fimmu.2020.01439] [PMID: 32655577]
[24]
Maideen NMP. Adjuvant therapies of COVID-19 - a literature review. Coronaviruses 2021; 2(10): e170821190562.
[http://dx.doi.org/10.2174/2666796702666210121144902]
[25]
Ahmad S, Zahiruddin S, Parveen B, et al. Indian medicinal plants and formulations and their potential against COVID-19–preclinical and clinical research. Front Pharmacol 2021; 11: 578970.
[http://dx.doi.org/10.3389/fphar.2020.578970] [PMID: 33737875]
[26]
Patgiri B, Umretia BL, Vaishnav PU, Prajapati PK, Shukla VJ, Ravishankar B. Anti-inflammatory activity of Guduchi ghana (aqueous extract of Tinospora cordifolia miers.). Ayu 2014; 35(1): 108-10.
[http://dx.doi.org/10.4103/0974-8520.141958] [PMID: 25364210]
[27]
Tamboli FA, More HN, Khairmode SS, et al. Chyawanprash: A traditional Indian bioactive herbal medicinal formulation to boost immunity and restore youthfulness. Tropical J Pharm Life Sci 2021; 8(1): 21-8.
[28]
Sharma R, Martins N, Kuca K, et al. Chyawanprash: A tradi-tional Indian bioactive health supplement. Biomolecules 2019; 9(5): 161.
[http://dx.doi.org/10.3390/biom9050161] [PMID: 31035513]
[29]
Pérez-Gómez J, Villafaina S, Adsuar JC, Merellano-Navarro E, Collado-Mateo D. Effects of Ashwagandha (Withania somnif-era) on vo2max: A systematic review and meta-analysis. Nutrients 2020; 12(4): 1119.
[http://dx.doi.org/10.3390/nu12041119] [PMID: 32316411]
[30]
Gundeti MS, Bhurke LW, Mundada PS, et al. AYUSH 64, a polyherbal ayurvedic formulation in influenza-like illness - results of a pilot study. J Ayurveda Integr Med 2020; S0975-9476(20)30025-5.
[http://dx.doi.org/10.1016/j.jaim.2020.05.010] [PMID: 33446377]
[31]
Gautam S, Gautam A, Chhetri S, Bhattarai U. Immunity against COVID-19: potential role of Ayush Kwath. J Ayurveda Integr Med 2022; 13(1): 100350.
[http://dx.doi.org/10.1016/j.jaim.2020.08.003] [PMID: 32837101]
[32]
Dalvi PD, Kulkarni MS, Jadhav SP. Literary review of Anu taila nasya. UJAHM 2015; 3(2): 42-5.
[33]
Poudel S, Yadav MP. Agastya haritaki rasayana: A critical re-view. J Drug Deliv Ther 2019; 9(1-s): 486-91.
[http://dx.doi.org/10.22270/jddt.v9i1-s.2283]
[34]
Suryavanshi SV, Barve K, Addepalli V, Utpat SV, Kulkarni YA. Triphala churna-a traditional formulation in ayurveda mitigates diabetic neuropathy in rats. Front Pharmacol 2021; 12: 662000.
[http://dx.doi.org/10.3389/fphar.2021.662000] [PMID: 34149415]
[35]
Verma P, Galib BP, Patgiri B, Prajapati PK. Shelf-life evaluation of Rasayana churna: A preliminary study. Ayu 2014; 35(2): 184-6.
[http://dx.doi.org/10.4103/0974-8520.146247] [PMID: 25558165]
[36]
Gupta A, Vedula S, Srivastava R, et al. Prospective, random-ized, open-label, blinded end point, two-arm, comparative clini-cal study to evaluate the efficacy and safety of a fixed ayurve-dic regimen (FAR) as add-on to conventional treatment in the management of mild and moderate COVID-19 patients. J Pharm Bioallied Sci 2021; 13(2): 256-67.
[PMID: 34349488]
[37]
Devpura G, Tomar BS, Nathiya D, et al. Randomized placebo-controlled pilot clinical trial on the efficacy of ayurvedic treat-ment regime on COVID-19 positive patients. Phytomedicine 2021; 84: 153494.
[http://dx.doi.org/10.1016/j.phymed.2021.153494] [PMID: 33596494]
[38]
Kankane DA, Singh DR, Gupta DA, Shrikhande B, Ganu D. Randomized controlled clinical trial to evaluate the potential of ayurvedic medicines in patients with mild symptoms of COVID-19. Eur J Mol Clin Med 2021; 8(3): 3017-27.
[39]
Patankar SB, Rangnekar H, Joshi K, et al. Efficacy and safety of polyherbal formulation as an add-on to the standard of care in mild to moderate COVID-19: A randomized, double-blind, pla-cebo-controlled trial. medRxiv 2021.
[http://dx.doi.org/10.1101/2021.05.14.21256900]
[40]
Shukla U, Ujjaliya N, Gupta P, et al. Efficacy and safety of guduchighan vati in asymptomatic and mild to moderate cases of COVID-19: A randomized controlled pilot study. OSF preprint 2021. 2021.
[http://dx.doi.org/10.31219/osf.io/c8f9h]
[41]
Chopra A, Tillu G, Chaudhary K, et al. Coadministration of AYUSH 64 as an adjunct to standard of care in mild and mod-erate COVID-19: A randomised, controlled, multicentric clinical trial. medRxiv 2021.
[http://dx.doi.org/10.1101/2021.06.12.21258345]
[42]
Reddy RG, Gosavi RV, Yadav B, et al. AYUSH-64 as add-on to standard care in asymptomatic and mild cases of COVID-19: A randomized controlled trial. OSF preprint 2021.
[http://dx.doi.org/10.31219/osf.io/pgraf]
[43]
Thakar A, Goyal M, Bhinde S, Chhotala Y, Panara K, Chaudhari S. Efficacy of ayush 64 as add-on therapy in early stage COVID 19-An open-label randomized controlled pilot study. OSF preprint 2021.
[http://dx.doi.org/10.31219/osf.io/t8wza]
[44]
Gupta A, Madan A, Yadav B, et al. Chyawanprash for the pre-vention of COVID-19 infection among healthcare workers: A randomized controlled trial. medRxiv 2021.
[http://dx.doi.org/10.1101/2021.02.17.21251899]
[45]
Dutt J, Ganatra B, Suthar N, et al. A randomized and compara-tive study to assess safety and efficacy of supplemental treat-ment of a herbal formulation - Aayudh Advance comprising es-sential oils in patients with corona virus 2019 (COVID-19). Contemp Clin Trials Commun 2021; 22: 100755.
[http://dx.doi.org/10.1016/j.conctc.2021.100755] [PMID: 33728385]
[46]
Kataria S, Sharma P, Ram JP, et al. A Pilot Clinical study of an add on ayurvedic formulation containing Guduchi and Pippali in mild to moderate COVID-19. J Ayurveda Integr Med 2022; 13(2): 100454.
[http://dx.doi.org/10.1016/j.jaim.2021.05.008] [PMID: 34127896]
[47]
Kavita V, Anubha C, Vikas N, et al. An Open label prospective interventional study to assess the prophylactic effect of Guduchi ghan vati in COVID-19: A community-based study in a containment zone of Himachal Pradesh, India. OSF preprint 2021.
[http://dx.doi.org/10.31219/osf.io/8vwsy]
[48]
Wanjarkhedkar P, Sarade G, Purandare B, Kelkar D. A prospec-tive clinical study of an ayurveda regimen in COVID 19 pa-tients. J Ayurveda Integr Med 2022; 13(1): 100365.
[http://dx.doi.org/10.1016/j.jaim.2020.10.008] [PMID: 33100779]
[49]
Jani H, Pandya D, Narwai K. Management of COVID-19 by ayurveda protocol-a case series. J Ayurveda Integr Med Sci 2020; 5(05): 572-6.
[50]
Kulkarni V, Sharma N, Modi D, Kumar A, Joshi J, Krishna-murthy N. A Community-based participatory research to assess the feasibility of ayurveda intervention in patients with mild-to-moderate COVID-19. medRxiv 2021.
[http://dx.doi.org/10.1101/2021.01.20.21250198]
[51]
Kumar R, Mittra S, Yadav R, et al. Effect of a novel ayurvedic preparation, Raj Nirvan Bati (rnb), on symptomatic patients of covid-19. Ann Hortic 2020; 13(1): 66-75.
[http://dx.doi.org/10.5958/0976-4623.2020.00011.0]
[52]
Balkrishna A, Bhatt AB, Singh P, Haldar S, Varshney A. Com-parative retrospective open-label study of ayurvedic medicines and their combination with allopathic drugs on asymptomatic and mildly-symptomatic COVID-19 patients. J Herb Med 2021; 29: 100472.
[http://dx.doi.org/10.1016/j.hermed.2021.100472] [PMID: 34055580]
[53]
Shrivastva S, Singh H, Muralidharan S, et al. A Retrospective analysis of ayurvedic clinical management of symptomatic COVID-19 patients. OSF preprint, 2021.
[http://dx.doi.org/10.31219/osf.io/zxktu]
[54]
Thakar A, Panara K, Patel F, et al. Add-on ayurveda treatment for early stage COVID-19: A single center retrospective cohort study from Gujarat, India. J Evid Based Integr Med 2021; 26: X211020685.
[http://dx.doi.org/10.1177/2515690X211020685] [PMID: 34057365]
[55]
Kumar A, Prasad G, Srivastav S, Gautam VK, Sharma N. A retrospective study on efficacy and safety of Guduchi ghan vati for Covid-19 asymptomatic patients. medRxiv 2020.
[http://dx.doi.org/10.1101/2020.07.23.20160424]
[56]
Joshi J, Payyappalimana U, Puthiyedath R. Potential for sup-portive ayurvedic care in hypoxemic COVID-19 patients. J Ayurveda Integr Med 2022; 13(2): 100447.
[http://dx.doi.org/10.1016/j.jaim.2021.05.001] [PMID: 33976504]
[57]
Jyothi PA, Dileep A, Devarajan D, et al. Three case reports of moderate COVID-19 infection managed through ayurvedic ap-proach. J Ayurveda Case Reports 2020; 3(3): 84-90.
[http://dx.doi.org/10.4103/jacr.jacr_57_20]
[58]
Mahto RR, Jyothi A, Dileep A, Shukla A, Gauri A. Efficacy of ayurveda and yoga in the management of SARS-CoV-2: Two case reports. J Ayurveda Case Reports 2020; 3(4): 127-32.
[http://dx.doi.org/10.4103/jacr.jacr_9_21]
[59]
Patil S. A case series sharing novel experience of treating viral pandemic cases of morbid, mid aged, mild, moderate & severe grade with only ayurvedic medicines. J Ayurveda Integr Med 2021; S0975-9476(21)00044-9.
[http://dx.doi.org/10.1016/j.jaim.2021.03.002] [PMID: 34024691]
[60]
Pradeep K, Reshma MA. Management of COVID-19 patients with mild and moderate symptoms through ayurveda: A Case Series. Int J of AYUSH Case Reports 2020; 4(4): 238-44.
[61]
Bentur SA, Mishra A, Kumar Y, Thakral S, Garg R. Integrative therapy based on yoga, ayurveda and modern Western medicine for treatment of high-risk cases of COVID-19: A telemedicine-based case series. OSF preprint. 2021.
[http://dx.doi.org/10.31219/osf.io/58btr]
[62]
Girija PL, Sivan N, Naik P, Murugavel YA, Thyyar MR, Krish-naswami CV. Standalone ayurvedic treatment of high-risk COVID-19 patients with multiple comorbidities: A case series. J Ayurveda Integr Med 2022; 13(1): 100466.
[http://dx.doi.org/10.1016/j.jaim.2021.06.006] [PMID: 34276163]
[63]
Rastogi S. Ayurveda co-interventions have supported complete recovery in severe COVID-19 infection with a chest Severity Score 18/25: A case report. J Ayurveda Integr Med 2022; 13(2): 100417.
[http://dx.doi.org/10.1016/j.jaim.2021.02.008] [PMID: 33727768]
[64]
Joshi JA, Puthiyedath R. Outcomes of ayurvedic care in a COVID-19 patient with hypoxia-a case report. J Ayurveda Integr Med 2022; 13(1): 100363.
[http://dx.doi.org/10.1016/j.jaim.2020.10.006] [PMID: 33071521]
[65]
Panda AK. Ayurvedic management of a patient with hypoxia and co-morbidities by home care through telehealth in 2nd wave of COVID-19-case report. J Ayurveda and Integr Med Sci 2021; 6(02): 207-11.
[66]
Pandey M, Kajaria D, Sharma C, Kadam S. Ayurvedic manage-ment of pregnant woman infected with coronavirus disease 2019 ((SARS-CoV-2) - A case report. J Ayurveda Integr Med 2021. Online ahead of print
[http://dx.doi.org/10.1016/j.jaim.2021.03.005] [PMID: 34149234]

Rights & Permissions Print Cite
Article Metrics
10
1
© 2024 Bentham Science Publishers | Privacy Policy